Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Share price shot up earlier and quite a few thousand purchased above 44 which all seems a bit peculiar.
Tomorrow was the date that the extension was given to the Doj regarding the witness subpoena. maybe some news coming.
Harsh Foxy.........LOL!
I am sure they do not think the DOJ are that easily swayed...
Collaborations happen all the time in the Pharma Sector...
run of the mill I would say!
A better day buywise roughly 4 to 1 but as usual the bots
are totally controlling the SP...very dull but have a feeling
we will get some good news before the holiday...GLA!
I see all this as Indivior trying to use these We support the blah blah RNS collaboration announcements as a way of trying to make themselves seen as positives in the Court case. Why not I say. Im sure anything positive can be used in Court to show they are really working in the interest of the users.
We are clearly the good guys. Hope we can say the same about the United States Department of Justice.
0 2 0
Https://www.pmlive.com/pharma_intelligence/As_the_opioid_crisis_grabs_the_headlines,_the_search_for_safe_treatments_continues_1318652
As the opioid crisis grabs the headlines, the search for safe treatments continues
Indivior’s Gilles Picard charts a path to greater patient access and new therapies
Gilles Picard
Tackling the global crisis of addiction is not a labour for the faint-hearted. Rising levels of drug use are barbed with the complexities of opioid dependence and wreathed with the unpredictable wildfires of lawsuits.
The opioid crisis resulted in an alarming spike in premature deaths in the US – 130 fatalities a day attributed to opioid-related overdoses at one stage – and has focused attention on how Europe will cope with advancing issues.
Four major pharmaceutical companies recently agreed to pay $260m to settle the first wave of actions in the US, with some experts predicting final bills of around $50bn across the industry.
It is hardly the easiest climate in which to market an opioid-based drug to treat addiction, while at the same time developing new treatments, but Indivior, the British-based firm that was part of Reckitt Benckiser until 2014, is undaunted.
Its share price took a massive hit when it was indicted by the US Justice Department earlier this year over its Suboxone Film therapy for opioid and heroin addiction, but its robust response, more of which later, has not deflected its mission to create safe and effective drugs to deal with, rather than inflame, a crisis.
The company’s mantra ‘Addiction is a treatable chronic condition, not a moral failure’ is sustaining its R&D work and Gilles Picard (pictured above), its head of global strategy and European operations, said the company is close to new registrations in Europe for opioid addiction products.
“We don’t use that as a slogan; it is what we believe,” he said. “We aim to change people’s lives with treatments for addiction and we are pleased to see that, in recent years, more people are of the view that addiction is a chronic condition and not some moral failing.
High success rate
“We also believe that over the next few years many more people will have access to opioid addiction therapies. But we need societal change as well as drug development and it is clear that some countries have better established routes to treatment than others.
“Opioid agonist treatment is scientifically underpinned and has a high success rate. The figure I use is 70-60-50. It reduces the mortality risk by 70%, lowers the risk of hepatitis C infection by 60% and has a 50% lower risk of relapse. Not many addiction treatments can produce those figures.”
European healthcare structures are better constructed to deter an opioid crisis from reaching US proportions, with stricter marketing regulations, stronger prescribing rules and a more open and progressive approach to opioid agonist therapy and other forms of harm reduction acting as effective
Good Article... It is quite clear INDV is a sound company
both ethically and financially! It is frustrating that the DOJ
have acted it seems without due dilligence.....BUT I do
think that there may well be such a good defence case
that they may yet dismiss their claim. Good to see we are
looking at Europe and have a positive outlook. Once
the DOJ saga is resolved we will see true value...I
hope that is not far off!
GLA!
Nope....also not opening, just google "the search for safe treatments continues" and you will see the article Johnny posted
GLA
cant read it
Thanks Johnny, this one might work.
https://www.pmlive.com/pharma_intelligence/As_the_opioid_crisis_grabs_the_headlines,_the_search_for_safe_treatments_continues_1318652
GLA
Apologies can't get the link to work
https://www.pmlive.com/pharma_intelligence/As_the_opioid_crisis_grabs_the_headlines,_the_search_for_safe_treatments_continues_1318652
https://www.pmlive.com/pharma_intelligence/As_the_opioid_crisis_grabs_the_headlines,_the_search_for_safe_treatments_continues_1318652